Latest news ...

Some of our recent news articles.

16th July 2020

Fosun Pharma's vaccine was accepted by China's NDA for clinical trial registration review

In March 2020, Fosun Pharma won the German BioNTech SE (referred to as "BioNTech" ) Authorized to exclusively develop and commercialize vaccine products for new coronaviruses based on its proprietary mRNA technology platform in mainland China, Hong Kong, Macao and Taiwan (same below). The vaccine is a biological product for prevention, and it is intended to be mainly used for the prevention of new coronavirus infection in people aged 18 and above. According to the latest public information of BioNTech, its new mRNA-based coronavirus vaccine has achieved positive results in phase 1/2 clinical trials. Among them, the two most advanced mRNA-based candidate vaccines BNT162b1 and BNT162b2 recently obtained the US Food and Drug Administration. (U.S. FDA) Fast Track designation is expected to become the fastest FDA approved mRNA vaccine. Subject to regulatory approval, BioNTech expects to start a global multi-center Phase 2b/3 clinical trial as early as later this month, with up to 30,000 participants expected to participate.

Read the full story »
12th July 2019

Fosun Pharma picks up GSK plant in China along with rights to make Epivir generic

Even as GlaxoSmithKline has opened its most advanced manufacturing site in Asia, it is selling an older plant in China to Shanghai Fosun Pharmaceutical. 

 Fosun Pharma announced that it has a deal with GSK to buy its Suzhou pharmaceutical factory in east China near Shanghai for ¥250 million ($36 million), reports. Fosun, among China’s largest drugmakers, said the plant produced revenue of  ¥656.1 million ($94.4 million) last year. 
Read the full story »
17th August 2017

China's Fosun, Shanghai Pharma circle Georgia drugmaker Arbor for U.S. beef-up

Fosun Pharma and Shanghai Pharma, the two Chinese companies previously rumored to be eyeing generics maker Stada, are back on the M&A radar. And rather than publicly denying their deal interest this time, the two have confirmed offers for U.S. drugmaker Arbor Pharma.
Read the full story »

About Us

SURIMS is the new name for Actex Pharma Services which was a consultancy established in 2003, supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own supplier on-boarding and supplier management activities. Further information on our software services please contact Tel: +353 87 294 0436 or email


Get in Touch

The Pharmaceutical Services Directory


© 2020 Surims Ltd | All Rights Reserved.